Targeting PD-L1+ neutrophils enhances anti-PD-1 efficacy, whereas combining anti-PD-L1 therapy with TAN depletion (e.g., anti-Ly6G antibodies) leads to potent tumour suppression in preclinical models (135). Here, PDCD1 is linked to neoplasm.